New therapeutic strategies in inflammatory bowel disease (IBD) have shifted from symptom control towards treat-to-target algorithms in order to optimize treatment results. The treatment of IBD has evolved with the development of tumor necrosis factor-α inhibitors beyond the conventional therapies. In spite of their long-term effectiveness, many patients do not respond to or cannot sustain treatment with these drugs, which have various side effects. Therefore, the development of new drugs targeting specific pathways in the pathogenesis of IBD has become necessary. Some novel biologics and small molecule drugs have shown potential in IBD clinical trials, providing safe and effective results. In addition, clinicians are now trying to target the dysbiotic microbiome of patients with IBD using fecal microbiota transplantation. New tools such as stem cells have also been developed, especially in the treatment of perianal CD. In the next few years, physicians will face an unprecedented number of options when choosing the best treatments for patients with IBD. This review provides an overview of recent advances in IBD treatment options.

**Key Words:** Inflammatory bowel diseases; Crohn disease; Colitis, ulcerative; Therapy

**INTRODUCTION**

Nonbiological therapies such as aminosalicylates, thiopurines, and steroids provide symptom improvement but do not change the overall disease course in inflammatory bowel diseases (IBDs) such as ulcerative colitis (UC) and Crohn’s disease (CD). Biological therapies that use monoclonal antibody targeting of tumor necrosis factor-α (TNF-α), such as infliximab, adalimumab, golimumab, and certolizumab pegol, were introduced in the late 1990s to induce and maintain remission. These biologics have led to the expectation that symptoms can be controlled and quality of life improved and even that the natural course of IBDs might eventually be changed.

However, approximately one third of IBD patients are primary non-responders to TNF-α inhibitor induction therapy, and another one third become secondary non-responders during TNF-α inhibitor maintenance therapy. In addition, although the safety profile of TNF-α inhibitors is generally acceptable, these drugs do have adverse effects relating to infections and malignancies.

As our understanding of the pathological mechanisms of IBDs has advanced, some novel drugs have shown potential in IBD clinical trials for providing safe and effective results. In addition, clinicians are now trying to target the dysbiotic microbiome of patients with IBD using fecal microbiota transplantation (FMT). New tools such as stem cells have also been developed, especially in the treatment of perianal CD. In the next few years, physicians will face an unprecedented number of options when choosing the best treatments for patients with IBD. This review provides an overview of recent advances in IBD treatment options.

**BIOLOGICS VERSUS SMALL MOLECULES**

Medications for IBD are classified into two categories, biologics and small molecule drugs. Biologics are monoclonal antibodies, large complex molecules that typically have a molecular weight of 150,000 Daltons, whereas small molecule drugs are less than 500 Daltons. Although biologics have a long half-life and high potency and selectivity, they are proteins that require a sterile living cell culture system and parenteral administration.
and they have immunogenicity. Because patient immune systems recognize the proteins as foreign bodies, antibodies to biologics can block their efficacy over time, causing treatment failure. On the other hand, small molecules are simply well-defined chemical structures produced by chemical synthesis. Although they have a short half-life and less potency than biologics, their advantages include an oral route of administration, low cost, and non-immunogenicity.

New biologics may offer opportunity for treatment with regard to the limitations of TNF-α inhibitors, even in patients who have previously failed with TNF-α inhibitors. Novel biologics include anti-integrins, anti-cytokines, and anti-mu-cosal vascular addressin cell adhesion molecule-1 (MAdCAM-1). Ami-nosalylates, thiopurines, and steroids are small molecule drugs that have been used for a long time. Thiopurines showed poorly defined maintenance effects in many previous studies of UC and CD. Novel orally administered small molecules have the potential to replace preexisting small molecule drugs. However, the efficacy, long-term safety profile, and cost-effectiveness of the new drugs remain to be elucidated. Novel small molecule drugs block immune cell communication or migration (Table 1, Fig 1).

**RECENTLY APPROVED NOVEL DRUGS**

1. **Monoclonal antibodies**

1) **Anti-adhesion molecules**

IBDs are characterized by the persistent recruitment of large quantities of leukocytes from the blood to the gut mucosa. Interactions between several surface molecules on T cells called integrins (α4β7) and tissue-specific adhesion molecules called ligands (MAdCAM-1), which are primarily expressed in endothelial venules, are responsible for the lymphocyte recruitment into the intestine seen in chronic intestinal inflammation. Therefore, leukocyte traffic control, using specific integrin inhibitors to prevent gut-homing T cells from moving out of the blood vessels, has been developed as a novel treatment for IBD.

Natalizumab (anti-integrin, α4 subunit)

Natalizumab is a nonselective recombinant humanized monoclonal IgG4 antibody against the integrin subunit α4 that blocks both α4β7 and α4β1. The α4β7/MAdCAM-1 interaction is gut specific. Phase 3 trials of natalizumab include ENACT-1, ENACT-2, and ENCORE. ENACT-1 was conducted to test the induction effect of natalizumab in 905 moderate to severe CD patients. At week 10, natalizumab showed favorable clinical response (56% [408/724] vs 49% [88/181], p=0.05) and similar remission (37% [267/724] vs 30% [55/181], p=0.12) compared with placebo. In the ENACT-2 comparing the maintenance effect at week 36, 339 patients who responded to natalizumab in ENACT-1 were divided into natalizumab and placebo groups; natalizumab demonstrated significantly higher clinical response (61% [103/168] vs 28% [48/170], p=0.001) and similar remission (44% [57/130] vs 26% [31/120], p=0.03) than placebo. The ENCORE that investigated the induction effects of natalizumab. In 509 moderate to severe CD patients treated with natalizumab or placebo, natalizumab achieved superior clinical response (48% [124/259] vs 32% [81/250], p=0.002) and remission (26% [68/259] vs 16% [40/250], p=0.002) than placebo at week 12.

Natalizumab also inhibits the migration of T cell lymphocytes to the central nervous system by blocking the α4β1/integrin interaction. As a result, progressive multifocal leukoencephalopathy caused by John Cun-ningham (JC) virus reactivation has been reported as a

| Table 1. Classification of Novel Drugs According to Molecular Mass and Mechanism   |
|-----------------------------------------------|-----------------------------------------------|
| **Block immune cell migration** | **Block immune cell communication** |
| **Biologics** | Anti-integrins: block receptors (integrins) on lymphocytes in recruiting from blood to tissue | Anti-cytokines: block signals (cytokines) outside from interacting with receptors on lymphocytes surface |
| | Anti-MAdCAM-1: block ligands (MAdCAM-1) on vascular endothelium in recruiting from blood to tissue | | |
| **Small molecule drugs** | S1P receptor modulators: trap lymphocytes in lymph nodes | JAKs inhibitor: block cell surface receptor signals (JAKs) inside lymphocytes |
| | | SMAD7 antisense oligonucleotide: block protein (SMAD7) from inhibit anti-inflammatory signaling inside lymphocytes |
| | | PDE4 inhibitor: block enzyme (PDE4) from catalyze cAMP from inflammatory cascade inside lymphocytes |

MAdCAM-1, mucosal vascular addressin cell adhesion molecule-1; S1P, sphingosine-1-phosphate; JAK, Janus kinase; SMAD, mothers against decapentaplegic homolog; PDE, phosphodiesterase; cAMP, cyclic adenosine monophosphate.
fatal adverse event associated with natalizumab.  

The estimated incidence of PML was 2 per 1,000 natalizumab-treated patients with multiple sclerosis, and having the JC virus antibody, prior use of immunosuppressants, and increased duration of natalizumab treatment were three major risk factors.  

Natalizumab was approved by U.S. Food and Drug Administration (FDA) in 2004 and temporarily withdrawn from the market in 2005 due to PML; it was reintroduced in 2006, but only in the United States.  

Natalizumab could be considered in patients who have had an inadequate response to or tolerability of conventional CD therapies and TNF-\(\alpha\) inhibitors, but it should not be used in combination with immunosuppressants or TNF-\(\alpha\) inhibitors. Only one open-label pilot study considered the effects of natalizumab in UC patients.  

After a single infusion, natalizumab was well tolerated and showed weak but positive efficacy up to week 12; six patients achieved clinical response at week 4, but only one of the 10 patients remained in remission at week 12.

Vedolizumab (anti-integrin, \(\alpha 4\beta 7\) subunit)

Vedolizumab is a selective IgG1 monoclonal antibody against \(\alpha 4\beta 7\) integrin. Vedolizumab showed effective induction and maintenance of remission in phase 3 trials with both UC (GEMINI-1) and CD (GEMINI-2). In GEMINI-1, 374 moderate
to severe UC patients were randomized, and 47.1% (106/225) of patients who received vedolizumab induction therapy had a clinical response at week 6 compared with 25.9% (38/149) of those in the placebo group (p<0.001).32 In maintenance therapy of 373 re-randomized induction responders, clinical remission was achieved at week 52 in 41.8% (51/122) and 44.8% (56/125) of patients who received vedolizumab every 8 and 4 weeks, respectively, and 15.9% (20/126) of the patients receiving placebo (p<0.001).32 In GEMINI-2, which had the same design as GEMINI-1, corresponding data were obtained in patients with moderate to severe CD; at week 6, 31.4% (69/220) in the vedolizumab group had a clinical response (vs 25.7% [38/148] in the placebo group, p=0.23) and at week 52, 39.0% (60/154) and 36.4% (56/154) of patients who received vedolizumab every 8 and 4 weeks, respectively, were in clinical remission (vs 21.6% [33/153]) in the placebo group, p<0.001 and p=0.004, respectively.33 A separate GEMINI-3 was conducted to evaluate the effects of vedolizumab induction in 315 CD patients who failed on TNF-α inhibitors.34 Although the remission rates were not significant at week 6 (15.2% [24/158] with vedolizumab vs 12.1% [19/157] with placebo, p=0.433), therapeutic benefits of vedolizumab were detectable at week 10 (26.6% [42/158] with vedolizumab vs 12.1% [19/157] with placebo, p=0.001). In post-hoc analyses of data from GEMINI-1, vedolizumab demonstrated greater efficacy as an induction and maintenance therapy in UC patients naive to TNF-α inhibitors than in those previously exposed to TNF-α inhibitors.35 The same trend of efficacy was demonstrated in CD in post-hoc analyses of data from GEMINI-2 and GEMINI-3.36 Notably, physicians should be aware of the potentially slow onset of action with vedolizumab, especially in CD. This is a predictable result because vedolizumab is an anti-adhesion molecule that blocks lymphocytes from moving blood to gut tissue. It takes time for pre-existing immune cells in the inflamed tissue to disappear. Therefore, combined therapy with faster-acting induction agents such as steroids might be a good choice in hospitalized patients with a high inflammatory burden who need a rapid response. However, no randomized controlled trial has yet compared such a combination therapy with vedolizumab monotherapy. Another option in acute severe colitis might be TNF-α inhibitors. Although vedolizumab showed superior outcomes when given to patient naive to TNF-α inhibitors, it is being positioned in some countries as a second-line biologic to follow TNF-α inhibitor therapy rather than as a first-line biological therapy. Excellent maintenance after successful induction with vedolizumab can be expected regardless of the type of IBD. Due to the gut-selective mechanism of vedolizumab, patients with extraintestinal manifestations might prefer other treatment options such as ustekinumab or a combination therapy with TNF-α inhibitors. The GEMINI long-term study is a continuing phase 3 trial, and two interim analyses were reported for the efficacy of vedolizumab in UC and CD. Among UC patients who responded to vedolizumab induction, 88% (120/136) and 96% (70/73) were in remission in weeks 104 and 152 after administration, respectively.37 Similarly, among CD patients, 83% (100/120) and 89% (62/70) were in remission in weeks 104 and 152, respectively.38 The ongoing ENTERPRISE (evaluation of fistula at week 30 after vedolizumab administration up to week 22, NCT02630966) and EARNEST (evaluation of pouchitis at week 34 after vedolizumab administration up to week 30 along with ciprofloxacin up to week 4, NCT02790138) phase 4 trials will determine its effectiveness for the treatment of specific complications of CD and UC, respectively.

The gut-selective action of vedolizumab has important clinical implications for its safety profile.39 In 5 years and more than 2,800 patients exposed to vedolizumab, no increased risk was found for any infection, including PML.40 Importantly, vedolizumab does not increase the risk of opportunistic infections, and the rate of malignancy is consistent with that generally observed in patients with IBD.40 For this reason, vedolizumab could be a good choice for IBD patients with contraindications to TNF-α inhibitors, such as a demyelinating disorder, congestive heart failure, lymphoma, and especially active or latent tuberculosis infections. On the other hand, one theoretical issue with the gut-specific mechanism of vedolizumab is the possibility of gastrointestinal infections and malignancies. However, in the published data, enteric infections were infrequent in vedolizumab-exposed patients, and the incidence of colorectal cancer was consistent with that generally seen in IBD patients.40 Recently, vedolizumab was approved by the U.S. FDA and the European Medicines Agency (EMA) for moderate to severe UC or CD patients who do not respond to conventional or TNF-α inhibitor therapy.

2) Anti-cytokine molecules

Interleukin (IL)-12 p35-p40 and IL-23 p19-p40 are pro-inflammatory heterodimeric cytokines that share a common p40 subunit and induce T helper cell (TH)1 and TH17 differentiation, respectively, thereby leading to T cell immune responses.41 These cytokines are expressed by dendritic cells and macrophages. They are increased in the gut mucosa with inflammation of IBD patients.42

Ustekinumab (anti-IL-12/IL-23)

Ustekinumab is a fully human IgG1k monoclonal antibody against the common p40 subunit of IL-12 and IL-23, and it reduces T cell activation.43 Ustekinumab demonstrated induction efficacy in both patients with TNF-α inhibitor failure (UNITI-1) and TNF-α inhibitor-naive (UNITI-2) and maintenance efficacy (IM-UNITI) in a phase 3 trial of moderate to severe CD patients who experienced failure or unacceptable side effects with conventional therapies.44 The rates of response at week 6 among patients receiving ustekinumab at a dose of either 130 mg or 6 mg/kg were significantly higher than the rate among patients receiving placebo in the UNITI-1 (34.3% [84/245],
chemical signals are not transmitted to the intracellular nucleus, which reduces gut inflammation.

Tofacitinib (JAK1/JAK3 inhibitor)

Tofacitinib is an orally administered small molecule that mainly inhibits JAK1 and JAK 3 and blocks the downstream effects of a large subset of proinflammatory cytokines including IL-2, IL-3, IL-4, IL-5, IL-6, IL-12, IL-15, IL-21, and interferon-γ.53 In a phase 3 trial, tofacitinib demonstrated efficacy in both inducing (OCTAVE-1 and OCTAVE-2) and maintaining (OCTAVE Sustain) remission in moderate to severe UC patients who had previously used conventional or TNF-α inhibitor therapies.54 In the OCTAVE-1 and OCTAVE-2 induction trials, 598 and 541 patients, respectively, were randomized. In OCTAVE-1, remission at week 8 occurred in 18.5% (88/476) of the patients in the tofacitinib 10 mg group versus 8.2% (10/122) in the placebo group (p=0.007); in OCTAVE-2, remission occurred in 16.6% (71/429) versus 3.6% (4/112, p<0.001), respectively. Notably, in both trials, the treatment effect was similar between those who had received previous TNF-α inhibitor therapy and those who had not. Further studies are needed to determine whether it is better to use tofacitinib before or after biologics. In addition, tofacitinib appeared to be a fast-acting induction agent, improving the partial Mayo Score after only 2 weeks of administration. Patients who completed the induction trials with a clinical response participated in OCTAVE Sustain. At week 52, clinical remission occurred in 34.3% (68/198) of the patients in the 5 mg tofacitinib group and 40.6% (80/197) of the patients in the 10 mg tofacitinib group versus 11.1% (22/198) of the patients in the placebo group (p<0.001 for both compared with placebo). In addition, across all three OCTAVE trials, both 5 mg and 10 mg of tofacitinib were superior to placebo for the induction and maintenance of mucosal healing. Because tofacitinib is a small molecule, it is not limited by immunogenicity or loss of response. The measurement of drug concentration might not be meaningful because the average drug concentrations of small molecules were similar regardless of remission.

Tofacitinib targets multiple cytokine pathways, which might increase the risk of infection. In the OCTAVE, infections occurred at higher rates with tofacitinib than with placebo, including herpes zoster.55 The 4.4 years data from global clinical trials of tofacitinib indicates a safety profile similar to that observed in UC patients treated with biologic agents, except for the dose-dependent higher incidence of herpes zoster infection (4.1; 95% confidence interval [CI], 3.1 to 5.2).55 Therefore, combination therapy with other broad immunosuppressants might not be advisable. In addition, similar to findings from rheumatoid arthritis, lipid profiles and cardiovascular events increased in patients who received tofacitinib, though the clinical relevance of those changes is uncertain.54,56 Therefore, it is worth paying particular attention to patient selection when considering tofacitinib as a long-term maintenance therapy. The long-term safety and ef-
Ficacy of tofacitinib is being evaluated in an on-going, open-label, long-term extension study (OCTAVE Open, NCT01470612). Tofacitinib was approved for the treatment of moderate to severe UC patients by the U.S. FDA in June 2018. On the other hand, in a 4-week phase 2 trial\(^6\) and phase 2b induction and maintenance trial\(^5\) with CD patients, tofacitinib had no clinical efficacy in induction compared with placebo.

**NOVEL DRUGS CURRENTLY IN LATE-PHASE DEVELOPMENT**

1. **Monoclonal antibodies**

   **1) Anti-adhesion molecules**

   Etrolizumab (anti-integrin, β7 subunit)

   Etrolizumab is a humanized IgG1 monoclonal antibody directed against the β7 subunit of the αβ7 and αEβ7 integrins, which interact with MAdCAM-1 and E-cadherin, respectively.\(^5\) E-cadherin is expressed on the intestinal epithelium. It serves as a ligand in the homing behavior of gut intraepithelial lymphocytes. Binding to both α4β7 and αEβ7 enables etrolizumab to block mucosal lymphocyte trafficking and intraepithelial leukocyte retention, respectively.\(^3\)

   Etrolizumab was evaluated in a phase 2 trial (EUCALYPTUS) of 124 moderate to severe UC patients who had not responded to conventional therapy, including two thirds of TNF-α inhibitors non-responders.\(^4\) Patients were assigned to receive 100 mg of etrolizumab at weeks 0, 4, and 8 or a 420 mg loading dose followed by 300 mg at weeks 2, 4, and 8, or placebo. No patients (0/41) in the placebo group had clinical remission at week 10, compared with 21% of the patients (8/39) in the etrolizumab 100 mg group (p=0.004) and 10% (4/39) of the patients in the 300 mg group (p=0.048). Adverse events occurred at a similar frequency in all three groups. The expression of E-cadherin in biopsy samples increased in patients in the etrolizumab groups who achieved clinical remission compared with those who did not (p=0.0022). Therefore, colonic biopsy could play a role as a predictive biomarker for better response to etrolizumab. Currently, several phase 3 trials for UC patients are being evaluated: a comparison of infliximab and etrolizumab (NCT02163759), a combination of etrolizumab and adalimumab (NCT02163759), the induction and maintenance of a clinical response in patients exposed to TNF-α inhibitors (HICKORY, NCT02100696), and response maintenance in patients naïve to TNF-α inhibitors (NCT02165215). Induction and maintenance (BERGAMOT, NCT02394028) and open-label extension (NCT02403323) trials are also under way for CD patients. Interim results from BERGAMOT cohort-1 showed tolerable safety and clinically meaningful endoscopic improvement up to week 14.\(^6\) αEβ7 and α4β7 are differentially expressed in T lymphocyte effector subsets in the peripheral blood and intestines, respectively, of IBD patients. Because etrolizumab has additional inhibitory effects on the αEβ7-mediated retention of lymphocytes in the gut epithelium compared with vedolizumab, it could inhibit inflammation in the intestine more strongly than vedolizumab. However, if β7 integrin is blocked, it could reduce gut specificity because αEβ7 is expressed by T cells in other tissues as well as in the intestines. Subsequent local infections outside the intestine can be a problem. Ongoing phase 3 trials (HICKORY, BERGAMOT) could determine whether latent infection is a significant adverse effect of etrolizumab.

   SHP-647 (PF-00547659, anti-MAdCAM-1)

   SHP-647 is a fully humanized monoclonal anti-MAdCAM IgG2 antibody directed against the gut-specific endothelial adhesion molecule MAdCAM-1.\(^5\) Phase 2 trials were conducted separately in UC and CD patients. In the TURANDOT, 357 moderate to severe UC patients were randomized to receive 7.5, 22.5, 75, or 225 mg of SHP-647 or placebo. At week 12, clinical remission rates were 11.3% (8/71), 16.7% (12/72), and 15.5% (11/71), and 5.7% (4/70) for 7.5, 22.5, 75, and 225 mg, respectively, versus 2.7% (2/73) in the placebo group (p=0.0425, p=0.0099, p=0.0119, p=0.1803, respectively, against placebo).\(^6\) However, in contrast, the OPERA study in 265 moderate to severe CD patients did not demonstrate any therapeutic benefits compared with placebo response.\(^5\) SHP-647 was well tolerated in long-term phase 2 trials in UC patients up to week 144 (TURANDOT-2, NCT01771809) and in CD patients up to week 72 (OPERA-2, NCT01298492). Phase 3 trials for CD induction therapy (CARMEN CD 305, NCT03559517 and CARMEN CD 306, NCT03566823) and UC induction (FIGARO UC 301, NCT03259334 and FIGARO UC 302, NCT03259308) and maintenance (FIGARO UC 303, NCT03290781) therapy are currently in the recruitment phase.

   **2) Anti-cytokine molecules**

   Risankizumab, brazikumab, mirikizumab, and guselkumab (anti-IL-23)

   Risankizumab is a fully humanized IgG1 monoclonal antibody directed against the p19 subunit of IL-23, similar to ustekinumab. Risankizumab was tested as an induction therapy for CD in a phase 2 trial of 121 moderate to severe CD patients who were randomized to receive 200 mg or 600 mg of risankizumab or placebo at weeks 0, 4, and 8.\(^5\) At week 12, 24% of the patients (10/41) who received 200 mg of risankizumab (p=0.31) and 37% (15/41) who received the 600 mg dose had clinical remission versus 15% (6/39) of the placebo group (p=0.0252). Notably, these results were obtained in a patient population in which 93% of patients had been previously treated with TNF-α inhibitors. Adverse effects of the risankizumab were similar to that of the placebo. A long-term extension trial showed clinical remission in 71% (44/62), clinical response in 81% (50/62), endoscopic remission in 35% (22/62), and endoscopic response in 55% (34/62) of patients.\(^5\) Phase 3 trials for induction and maintenance therapy in moderate to severe CD patients
A phase 2a trial evaluated brazikumab in 119 moderate to severe CD patients who had failed with TNF-α inhibitors. Patients were assigned to receive either 700 mg of brazikumab or placebo at weeks 0 and 4. At week 8, clinical response had been achieved in 49.2% (29/59) of patients receiving brazikumab compared with 26.7% (16/60) receiving placebo (p=0.01). The most common adverse events were headache and nasopharyngitis. High level of serum IL-22, a cytokine whose expression is induced by IL-23, was a predictive biomarker for a better response to brazikumab. However, another phase 2b study with different doses and regimens was terminated (NCT02574637). A new phase 2 trial (EXPEDITION, NCT03616821) for moderate to severe UC patients is currently in recruiting.

Mirikizumab is currently being studied in a phase 2 trial of CD patients (SERENITY, NCT02891226). In UC, a phase 2 trial (NCT02589665) has been completed, but the results have not yet been released. Three phase 3 trials for induction (LUCENT-1, NCT03518086), maintenance (LUCENT-2, NCT03524092), and long-term extension (LUCENT-3, NCT03519945) in moderate to severe UC patients recently started recruiting. Clinical trials of other IL-23p19 antibodies, guselkumab for CD (phase 2, GALAXI-1, NCT03466411) and UC (phase 2, VEGA, NCT03662542) are currently in recruiting.

Briakinumab (anti-IL-12/IL-23)

Like ustekinumab, briakinumab is a human monoclonal antibody against the common p40 subunit of IL-12 and IL-23. In a preliminary phase 2a trial, briakinumab showed no significant difference for induction of remission in moderate to severe CD. Another phase 2b trial also failed to show significant difference in remission rate at induction phase in 24 moderate to severe CD patients. At week 6, 400 mg and 700 mg of briakinumab enter clinical remission in 13.3% (6/45) and 17.3% (24/139), respectively, compared with placebo 8.7% (4/46) (p=0.455 and p=0.157, respectively, compared with placebo). However, at week 12, a significantly greater proportion of patients in the briakinumab 400 mg (28.9%, p=0.030) but not the 700 mg group (22.3%, p=0.087) were in remission compared with patients in the placebo group (10.9%). In both trials, briakinumab appear to be safe. In UC, no clinical trial has yet been reported.

2. Small molecules

1) Blockage of downstream signaling

Filgotinib, upadacitinib (JAK1 inhibitor)

Filgotinib, a selective JAK1 inhibitor, demonstrated efficacy in 174 moderate to severe CD patients in a phase 2 trial (FITZROY). Clinical remission at week 10 was achieved in 47% (60/128) of patients treated with 200 mg of filgotinib versus 23% (10/44) of patients treated with placebo (p=0.0077). Up to week 20, filgotinib showed an acceptable safety profile. The effect was much less impressive among patients with previous exposure to TNF-α inhibitors (37% vs 29% for filgotinib and placebo, respectively). Further phase 2 trials in fistulizing CD (NCT03077412) and small bowel disease CD (NCT03046056), as well as several phase 3 trials in UC (SELECTION-1, NCT02914522 and SELECTIONLTE, NCT02914535) and CD (DIVERSITY-1, NCT02914561 and DIVERSITYLTE, NCT02914600) are ongoing.

Upadacitinib showed efficacy as an induction therapy in 180 moderate to severe CD patients in a phase 2 trial (CELEST, NCT02365649). At week 16 of induction, numerically more patients on 6 mg of upadacitinib twice a day achieved clinical remission compared with placebo (27% [10/37] vs 11% [4/37], p=0.1). However, significantly more patients achieved endoscopic remission with 24 mg of upadacitinib twice a day compared with placebo (22% [8/36] vs 0% [0/37], p=0.01). The safety profile was as expected with a JAK inhibitor in this population. Currently, several phase 3 trials for induction are ongoing in CD patients both with (NCT03345836) and without (NCT03345849) TNF-α inhibitors experience, and maintenance (NCT02782663) and long-term extension (NCT03345823) therapy trials are also ongoing. In addition, phase 3 trials for UC (NCT02819635, NCT03653026, and NCT03006068) are also being evaluated.

Mongersen (SMAD7 antisense oligonucleotide)

Transforming growth factor β1 (TGF-β1) is a pleiotropic cytokine that has anti-inflammatory properties and plays an important role in cell homeostasis. In IBD, TGF-β1 is highly produced but unable to signal through the TGF-β receptor-associated SMAD pathway to suppress the production of inflammatory molecules. Abnormally decreased activity of TGF-β1 in IBD is related to increased levels of SMAD7, an intracellular protein that binds to TGF-β receptors and inhibits TGF-β1-associated and SMAD-associated signaling. Therefore, SMAD7 is a potential target for the suppression of IBD-associated inflammation.

Mongersen is a novel oral drug containing the specific SMAD7 antisense oligonucleotide. A phase 2 trial was conducted among 166 moderate to severe CD patients who were assigned to one of three doses of mongersen (10, 40, or 160 mg/day) or placebo for 2 weeks. Clinical remission rates at day 15 were 55% (22/40) and 65% (28/43) for the 40 and 160 mg/day groups, respectively, versus 10% (4/42) in the placebo group (p<0.001 for both comparisons with placebo), but the 10 mg dose of mongersen (12%, 5/41) failed to show significant efficacy. Most adverse effects were related to either symptoms or complications of CD. However, a phase 3 clinical trial evaluating the efficacy and safety of mongersen in CD patients was recently terminated and withdrawn because it failed to show anything like the phase 2 successes (NCT02596893, NCT02974322, and NCT02641392). A small phase 2 open label trial for UC has been completed (NCT02601300), and the results have not yet...
been released.

Apremilast (PDE4 inhibitor)

PDE4 is one of the enzymes that catalyze the breakdown of cyclic adenosine monophosphate (cAMP) to AMP in several types of cells, including inflammatory cells, and is considered to be an important player in the intracellular inflammatory cascade. PDE4 inhibitors increase intracellular levels of cAMP, which consequently downregulates the release of pro-inflammatory cytokines in the mucosa of IBD patients.7

Apremilast specifically targets PDE4 and could show efficacy in IBD treatment. Interim results of a phase 2 study (NCT02289417) were recently presented and demonstrated its effectiveness in 170 moderate to severe UC patients.70 At week 12, total Mayo Score remission was achieved in 31.6% (18/57) of the group receiving 30 mg of apremilast twice a day compared with 13.8% (8/58) of the placebo group (p=0.05). However, the group receiving 40 mg of apremilast twice a day (21.8% of 55 patients) did not show significant difference. There were no new safety reports. In CD, no clinical trial has yet been reported.

2) Anti-trafficking molecules

S1P is a bioactive sphingolipid that mediates cellular responses in different cell types via extracellular activation of S1P receptor 1 (S1P1) to S1P5.77 S1P1, S1P3, and S1P5 are involved in regulating the immune system and expressed on lymphocytes and endothelial cells in lymph nodes, whereas S1P2 and S1P3 could be associated with cardiovascular, pulmonary, and cancer-related risks.85 Lymphocytes migrate from regional lymph nodes into the blood vessels according to the S1P concentration gradient.84 Stimulation of S1P1 on lymphocytes results in the internalization and degradation of the target receptor.84 Consequently, lymphocytes could not follow the S1P gradient on the lymphatic endothelium, which induces peripheral lymphocyte sequestration and decreases the number of activated lymphocytes recruiting to the intestine.79

Ozanimod, etrasimod (S1P receptor modulator)

Ozanimod is a novel, oral, small-molecule S1P1 and S1P5 agonist, mainly S1P1.83 A phase 2 trial (TOUCHSTONE) evaluated the induction and maintenance treatment of ozanimod in 197 moderate to severe UC patients.84 The patients were randomized to placebo, 0.5, or 1 mg of ozanimod daily. At week 8, clinical remission was achieved in 16% (11/67) of the patients who received 1 mg of ozanimod and 14% (9/65) of those who received 0.5 mg of ozanimod, as compared with 6% (4/65) of those who received placebo (p=0.048 and p=0.14, respectively, compared with placebo). At week 32, clinical remission was 21% in the group (14/67) that received 1 mg of ozanimod, 26% (17/65) in the group that received 0.5 mg of ozanimod, and 6% (4/65) in the group that received placebo (p=0.01 and p=0.002, respectively, compared with placebo). Ozanimod was well tolerated, and the most common adverse events were anemia and headache. Interim results from a phase 3 long-term open-label trial (TOUCHSTONE, NCT02531126) indicated that 1 mg ozanimod appears to be well tolerated, with evidence of rapid onset and durable efficacy up to week 104 with no rectal bleeding in 88.2% patients.85 A phase 3 trial of ozanimod as an induction and maintenance therapy for UC is currently ongoing (NCT02435992). Initial results from a phase 2 trial (STEPSTONE, NCT02531113) of 69 patients treated with ozanimod for moderate to severe CD demonstrated meaningful clinical and endoscopic improvements at week 12 in both biologic-naïve and biologic-experienced patients.86 Currently, phase 3 trials of ozanimod in moderate to severe CD patients are ongoing for induction and maintenance, along with an open-label long-term efficacy and safety trial (NCT03440372, NCT03440385, NCT03464097, and NCT03467958).

Etrasimod is a compound similar to ozanimod that selectively targets S1P1, S1P3, and S1P5, in vitro assays.87 Initial results from a phase 2 trial (OASIS, NCT201447302) in 156 moderate to severe UC patients treated with etrasimod showed that it was effective in achieving dose-dependent improvements in endoscopic appearance (22.5% (12/52), 41.8% (21/50), and 17.8% (10/54) for etrasimod 1 mg, 2 mg, and placebo, respectively, p=0.306, p=0.03 compared with placebo).88 Etrasimod was safe and well tolerated in this short-term study. Etrasimod is currently being tested in a parallel extension phase 2 trial for moderate to severe UC (NCT02536404). In CD, no clinical trials have yet been reported.

OTHERS

1. Novel combinations

Drug combinations, such as those commonly used in the treatment of diabetes or hypertension, could be a way to take advantage of the strengths and make up for the weaknesses of both biologics and small molecules. The SONIC and SUCCESS trials combining infliximab and azathioprine showed the potential of combination therapy.87,88 On the other hand, the DIAMOND trial, which combined adalimumab with azathioprine, failed to show clinical improvement in the remission rate compared with adalimumab monotherapy in CD patients, though mucosal healing was significantly higher in the combination group.89 Similarly, GEMINI-1 and 2 showed that concomitant immunosuppressive therapy with vedolizumab was associated with decreased immunogenicity.90 The co-administration of immunosuppressive drugs at baseline decreased the ADA positivity rate by 1%, from 4% to 3%. Further studies are needed to determine whether combination therapy with immunosuppressive drugs offers the same clinical advantages for vedolizumab as seen with infliximab/azathioprine combination therapy. Ustekinumab appears to be less immunogenic than
the TNF-α inhibitors. In the IM-UNITI, the incidence of ADAs to ustekinumab at week 44 was low, only 2.3% of patients (27/1,154). Although combination therapy with immunosuppressives might reduce ADAs compared with ustekinumab monotherapy, the clinical benefit remains unknown.

The availability of several biologics for the treatment of IBDs offers the possibility of combining them to simultaneously antagonize different pathways, which could produce additive or synergistic effects for the refractory disease. In 2007, Sands et al. conducted a randomized trial of the efficacy and safety of concurrent natalizumab in 79 CD patients not in remission while receiving infliximab. That study showed that symptoms tended to improve in the natalizumab/infliximab arm (52 patients) compared with the placebo/infliximab arm (27 patients) (CDAI score reduction, –37.7 vs +3.5, p=0.084), with comparable adverse effects. Since then, several anecdotal case reports of combinations such as infliximab plus vedolizumab, etanercept plus vedolizumab, and ustekinumab plus infliximab or adalimumab have been reported. Recently, an open label phase 4 trial evaluating the triple combination therapy of vedolizumab, adalimumab, and methotrexate (EXPLORER, NCT02764762) has started enrolling 60 patients with high risk CD. However, that combination therapy faces some potential issues, such as blocking opposing pathways and subsequent increased side effects, in addition to increased costs.

### 2. Fecal material transplantation

FMT is currently suggested in the guideline as a treatment option in refractory *Clostridium difficile*-associated colitis. Although FMT was also proposed as a treatment method for IBD about 30 years ago, interest and investigation of it as a potential treatment for IBD has grown only in the past few years. A meta-analysis of 53 studies, 41 in UC, 11 in CD, and 4 in pouchitis, comprising 661 IBD patients showed that 36% of UC patients (201/555), 50.5% of CD patients (42/83), and 21.5% (5/23) of pouchitis patients undergoing FMT achieved clinical remission. In a sub-analysis of 24 studies, microbiota analyses showed increased diversity and a shift in the recipient microbiota profile toward the donor. In another meta-analysis of 4 randomized controlled trials for UC, FMT was associated with higher clinical remission (risk ratio, 0.76; 95% CI, 0.62 to 0.93) and endoscopic remission (risk ratio, 0.85; 95% CI, 0.69 to 1.05) compared with placebo. No significant increase in serious adverse events was observed. FMT has showed promise as a treatment for IBD, especially UC, in many studies. FMT as a treatment for UC appears very promising, especially with multiple infusions administered via the lower gastrointestinal tract. The role of FMT in CD remains unclear yet. Most patients in the studies done so far had mild to moderate UC, and it is unclear whether the efficacy will be similar, better, or worse in patients with severe disease. Some unanswered questions require fur-

### Table 2. Pipeline of Novel Pharmacologic Treatment Agents for Inflammatory Bowel Disease

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Drug</th>
<th>Type</th>
<th>Target</th>
<th>Route</th>
<th>Current status in IBD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-adhesion</td>
<td>Natalizumab</td>
<td>Chimeric mAb</td>
<td>Anti-integrin (α4 subunit)</td>
<td>IV</td>
<td>Phase 2a</td>
</tr>
<tr>
<td>molecules</td>
<td>Vedolizumab</td>
<td>Chimeric mAb</td>
<td>Anti-integrin (α4β7 subunit)</td>
<td>IV</td>
<td>Approved</td>
</tr>
<tr>
<td></td>
<td>Etrolizumab</td>
<td>Chimeric mAb</td>
<td>Anti-integrin (β7 subunit)</td>
<td>IV/SC</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>SHP-647</td>
<td>Fully human mAb</td>
<td>Anti-MAdCAM-1</td>
<td>SC</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Anti-cytokine</td>
<td>Ustekinumab</td>
<td>Fully human mAb</td>
<td>Anti-IL-12/IL-23 (p40)</td>
<td>IV/SC</td>
<td>Phase 3</td>
</tr>
<tr>
<td>molecules</td>
<td>Risankizumab</td>
<td>Fully human mAb</td>
<td>Anti-IL-23 (p19)</td>
<td>IV/SC</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>Brazikumab</td>
<td>Fully human mAb</td>
<td>Anti-IL-23 (p19)</td>
<td>IV/SC</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>Mirikizumab</td>
<td>Chimeric mAb</td>
<td>Anti-IL-23 (p19)</td>
<td>IV/SC</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Gusekumab</td>
<td>Fully human mAb</td>
<td>Anti-IL-23 (p19)</td>
<td>IV/SC</td>
<td>Phase 2</td>
</tr>
<tr>
<td>Blockage of</td>
<td>Tofacitinib</td>
<td>Small molecule</td>
<td>JAK1/JAK3 inhibitor</td>
<td>Oral</td>
<td>Approved</td>
</tr>
<tr>
<td>downstream</td>
<td>Filgotinib</td>
<td>Small molecule</td>
<td>JAK1 inhibitor</td>
<td>Oral</td>
<td>Phase 3</td>
</tr>
<tr>
<td>signaling</td>
<td>Upadacitinib</td>
<td>Small molecule</td>
<td>JAK1 inhibitor</td>
<td>Oral</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>Mongersen</td>
<td>Small molecule</td>
<td>SMAD7 antisense oligonucleotide</td>
<td>Oral</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>Apremilast</td>
<td>Small molecule</td>
<td>PDE4 inhibitor</td>
<td>Oral</td>
<td>Phase 2</td>
</tr>
<tr>
<td></td>
<td>Etrazimod</td>
<td>Small molecule</td>
<td>S1P receptor modulator</td>
<td>Oral</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Anti-trafficking</td>
<td>Ozanimod</td>
<td>Small molecule</td>
<td>S1P receptor modulator</td>
<td>Oral</td>
<td>Phase 2</td>
</tr>
</tbody>
</table>

IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; mAb, monoclonal antibody; IV, intravenous; SC, subcutaneous; MAdCAM-1, mucosal vascular addressin cell adhesion molecule-1; IL, interleukin; JAK, Janus kinase; SMAD, mothers against decapentaplegic homolog; PDE, phosphodiesterase; S1P, sphingosine-1-phosphate.
ther research before FMT can be considered for use in clinical practice. For example, it is unclear whether pooled or single donor is better. To date, no trials have attempted a microbiome analysis-informed strategy for donor selection. In addition, if repeated FMT is needed because IBD is a chronic disease, how many and how frequently will they be required, and what is the most effective infusion method, duodenal infusion, colonoscopic infusion, or enema? Do encapsulated stool pills work as an endoscopic FMT? Above all, long-term durability and safety remain unclear. Therefore, additional well-designed controlled trials of FMT in IBD are needed and many new trials are already in progress.

3. Stem cell transplantation

Recently, mucosal healing has become a required part of clinical response and a treatment goal based on treat-to-target therapeutic strategies in IBD.10 In line with these tactics, new stem cell therapy that can promote mucosal tissue regeneration has been highlighted in IBD.10 Stem cell biology can be applied using two different methods. First, hematopoietic stem cell transplantation (HSCT) has been considered for the treatment of refractory CD. Myeloablation of the subject patient, followed by HSCT could set the patient's immunological condition back to before the disease developed. A phase 3 trial (ASTIC) in 45 patients with refractory CD was terminated because no significant improvement was found in sustained disease remission at 1 year compared with conventional therapy (8.7% of 23 patients vs 4.5% of 22 patients, p=0.60), with increased toxicity including one fetal mortality.31 A phase 2 trial (MASCT-CD, NCT03219359) combining HSCT with vedolizumab to improve the chances of achieving and maintaining the remission has begun and is in recruitment. Second, mesenchymal stem cell transplantation (MSCT) is in clinical trials to treat UC and luminal CD (intravenous administration, allogenic) or fistulizing CD (intralesional injection, autologous). MSCT can exhibit both immunoregulatory functions and tissue regenerative functions upon transplantation and can be widely used for allogenic transplantation because of its low immunogenicity. A phase 3 trial of 212 CD patients demonstrated that intralesional injectable autologous MSCT is an effective and safe treatment compared with placebo for complex perianal fistulas in patients who did not respond to conventional or biological treatments.10 At week 24, remission with closure of all treated external openings was achieved in 50% (53/107) and 34% (36/105) (p=0.024) of the MSCT and placebo groups, respectively. A phase 3 trial (NCT00482092) of 330 moderate to severe CD patients used an intravenous infusion of allogenic MSCT delivered through a vein in the arm of healthy adult donors and is expected to report favorable data in the near future. Currently, intralesional autologous MSCT has been commercialized for perianal fistulizing CD and many stem cell-related trials are underway.

CONCLUSION

The newly approved and potentially novel drugs for the treatment of IBD described above are summarized in Table 2. New therapeutic strategies are evolving including early diagnosis, early intervention, tight control of biomarkers, and treat-to-target algorithms in order to optimize treatment results, and available therapeutic options for IBD are expanding rapidly. It might soon be possible to achieve those new therapeutic strategies and goals with the support of novel drugs, microbiome manipulations, and stem cells targeting specific pathways in IBD pathogenesis. A new, challenging era is coming for clinicians who must choose the best therapy for their IBD patients. Physicians involved in the management of IBD should have expertise to understand and properly apply the various treatment options in the near future.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES


85. Fosters of distinction P-001 to P-018. Am J Gastroenterol 2018;113:S1-S5.


